JP2016513090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513090A5 JP2016513090A5 JP2015556243A JP2015556243A JP2016513090A5 JP 2016513090 A5 JP2016513090 A5 JP 2016513090A5 JP 2015556243 A JP2015556243 A JP 2015556243A JP 2015556243 A JP2015556243 A JP 2015556243A JP 2016513090 A5 JP2016513090 A5 JP 2016513090A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- nanoparticles
- nanoparticle
- core
- medically useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims description 115
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 159000000003 magnesium salts Chemical class 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 150000003384 small molecules Chemical class 0.000 claims description 18
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 108010088751 Albumins Chemical class 0.000 claims description 13
- 102000009027 Albumins Human genes 0.000 claims description 13
- 150000002632 lipids Chemical class 0.000 claims description 13
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 12
- 239000004137 magnesium phosphate Substances 0.000 claims description 12
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 12
- 229960002261 magnesium phosphate Drugs 0.000 claims description 12
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 229920000249 biocompatible polymer Polymers 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 11
- 235000014633 carbohydrates Nutrition 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108091005461 Nucleic proteins Proteins 0.000 claims description 7
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 108010033040 Histones Proteins 0.000 claims description 5
- 108010007568 Protamines Proteins 0.000 claims description 5
- 102000007327 Protamines Human genes 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 5
- 229940048914 protamine Drugs 0.000 claims description 5
- 108020004491 Antisense DNA Proteins 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims description 4
- 239000003816 antisense DNA Substances 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 4
- 235000011010 calcium phosphates Nutrition 0.000 claims description 4
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 2
- 108091030071 RNAI Proteins 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 4
- 230000009368 gene silencing by RNA Effects 0.000 claims 4
- 229920002477 rna polymer Polymers 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 3
- 239000003960 organic solvent Substances 0.000 claims 2
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- -1 DNA-RNA hybrid Proteins 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 230000008236 biological pathway Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361761012P | 2013-02-05 | 2013-02-05 | |
| US61/761,012 | 2013-02-05 | ||
| PCT/US2014/014751 WO2014123935A1 (en) | 2013-02-05 | 2014-02-05 | Biodegradable and clinically-compatible nanop articles as drug delivery carriers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513090A JP2016513090A (ja) | 2016-05-12 |
| JP2016513090A5 true JP2016513090A5 (enExample) | 2017-03-02 |
| JP6507102B2 JP6507102B2 (ja) | 2019-04-24 |
Family
ID=51300093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556243A Active JP6507102B2 (ja) | 2013-02-05 | 2014-02-05 | 薬物送達キャリアとしての生分解性でかつ臨床上適合性のナノ粒子 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11001840B2 (enExample) |
| EP (2) | EP3845248A1 (enExample) |
| JP (1) | JP6507102B2 (enExample) |
| KR (1) | KR20150132131A (enExample) |
| AU (2) | AU2014215421A1 (enExample) |
| CA (1) | CA2899155A1 (enExample) |
| ES (1) | ES2873600T3 (enExample) |
| IL (1) | IL240148A0 (enExample) |
| MX (1) | MX2015010083A (enExample) |
| RU (1) | RU2015137815A (enExample) |
| SG (2) | SG10201706968UA (enExample) |
| WO (1) | WO2014123935A1 (enExample) |
| ZA (1) | ZA201506530B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014123935A1 (en) | 2013-02-05 | 2014-08-14 | 1Globe Health Institute Llc | Biodegradable and clinically-compatible nanop articles as drug delivery carriers |
| WO2015013673A1 (en) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3183007B1 (en) | 2014-08-19 | 2020-06-17 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| EP3247796A4 (en) * | 2015-01-14 | 2018-07-11 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
| KR102617833B1 (ko) | 2016-05-06 | 2023-12-27 | 엑시큐어 오퍼레이팅 컴퍼니 | 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| US10800817B2 (en) | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
| EP3568122B1 (en) * | 2017-01-10 | 2023-10-04 | Dukebox SP. Z O.O. | A method of manufacturing a suspension of nanoparticles of potassium salt or magnesium salt |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| KR102120482B1 (ko) | 2018-10-05 | 2020-06-08 | 씨제이제일제당 (주) | 생분해성 고분자 나노입자를 포함하는 메모리 소자 및 이의 제조방법 |
| JP2022540665A (ja) * | 2019-07-12 | 2022-09-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 機能化されたナノ粒子および細菌感染症の治療におけるその使用 |
| WO2021067952A1 (en) * | 2019-10-04 | 2021-04-08 | The University Of Chicago | Targeted nanomedicine for treating vascular disorders |
| EP4100021A4 (en) * | 2020-02-03 | 2023-11-15 | Rutgers, the State University of New Jersey | MICRORNA-7 COMPOSITIONS FOR PROMOTING FUNCTIONAL RECOVERY AFTER SPINAL CORD INJURY AND METHODS OF USE THEREOF |
| US11998615B2 (en) | 2021-04-14 | 2024-06-04 | The Board Of Trustees Of The Leland Stanford Junior University | Functionalized nanoparticles and their use in treating bacterial infections |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219577A (en) | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5879715A (en) * | 1997-09-02 | 1999-03-09 | Ceramem Corporation | Process and system for production of inorganic nanoparticles |
| DE19856432A1 (de) * | 1998-12-08 | 2000-06-15 | Basf Ag | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen |
| DE19912502A1 (de) | 1999-03-19 | 2000-09-21 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung |
| AU2002214854A1 (en) | 2000-10-25 | 2002-05-06 | Inex Pharmaceuticals Corporation | Lipid formulations for target delivery |
| IN192520B (enExample) * | 2001-08-01 | 2004-04-24 | Univ Delhi | |
| SG190613A1 (en) | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| ATE470433T1 (de) | 2004-02-13 | 2010-06-15 | Nod Pharmaceuticals Inc | Partikel mit kern aus calciumphosphat- nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung |
| US7611690B2 (en) | 2005-01-04 | 2009-11-03 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US20110081410A1 (en) | 2005-06-28 | 2011-04-07 | St. Marianna University, School Ofmedicine | Therapeutic agent for local inflammation |
| CN100435784C (zh) | 2005-07-25 | 2008-11-26 | 管晓虹 | 含有和包封中药成分的无机盐纳米粒子的制备方法 |
| WO2008045806A2 (en) * | 2006-10-06 | 2008-04-17 | Microislet, Inc. | Multilayered polyelectrolyte-based capsules for cell encapsulation and delivery of therapeutic compositions |
| MX2009011218A (es) | 2007-04-17 | 2010-02-11 | Baxter Int | Microparticulas de acido nucleico para administracion pulmonar. |
| US20110038939A1 (en) * | 2007-07-16 | 2011-02-17 | Northeastern University | Therapeutic stable nanoparticles |
| ES2873350T3 (es) * | 2007-08-27 | 2021-11-03 | 1Globe Health Inst Llc | Composiciones de ARN interferente asimétrico y usos de las mismas |
| EP2197454A4 (en) | 2007-09-25 | 2012-07-04 | Idexx Lab Inc | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES |
| JP4647706B2 (ja) | 2007-12-14 | 2011-03-09 | 江崎グリコ株式会社 | α−リポ酸ナノ粒子およびその調製方法 |
| US20110038941A1 (en) | 2007-12-27 | 2011-02-17 | The Ohio State University Research Foundation | Lipid Nanoparticle Compositions and Methods of Making and Using the Same |
| KR20110026424A (ko) | 2008-05-13 | 2011-03-15 | 유니버시티 오브 워싱톤 | 중합체 캐리어 |
| JP2012509904A (ja) | 2008-11-26 | 2012-04-26 | ユニバーシティ・オブ・カンザス | 核酸送達組成物および核酸送達法 |
| ES2381022T3 (es) | 2008-12-19 | 2012-05-22 | Biolitec Ag | Nanopartículas de fosfato de calcio como vehículo de colorantes para la terapia fotodinámica |
| US9937128B2 (en) * | 2009-08-03 | 2018-04-10 | The University Of North Carolina At Chapel Hill | Liposomes comprising a calcium phosphate-containing precipitate |
| JP2013504337A (ja) * | 2009-09-14 | 2013-02-07 | ナノハイブリッド カンパニー リミテッド | 標的特異的ｓｉＲＮＡ−層状無機水酸化物ナノハイブリッド、その製造方法、及びナノハイブリッドを含有する腫瘍治療用の医薬組成物 |
| JP5491119B2 (ja) * | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| WO2011140024A2 (en) * | 2010-05-03 | 2011-11-10 | University Of Utah Research Foundation | Nanoparticles produced from recombinant polymers and methods of making and using the same |
| WO2013040295A2 (en) * | 2011-09-14 | 2013-03-21 | University Of South Florida | Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation |
| CA2853689C (en) | 2011-11-04 | 2020-06-30 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| US20130243699A1 (en) * | 2011-12-07 | 2013-09-19 | Regents Of The University Of Minnesota | Biodegradable Magnetic Nanoparticles and Related Methods |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| WO2014123935A1 (en) | 2013-02-05 | 2014-08-14 | 1Globe Health Institute Llc | Biodegradable and clinically-compatible nanop articles as drug delivery carriers |
-
2014
- 2014-02-05 WO PCT/US2014/014751 patent/WO2014123935A1/en not_active Ceased
- 2014-02-05 EP EP20204049.9A patent/EP3845248A1/en active Pending
- 2014-02-05 US US14/765,763 patent/US11001840B2/en active Active
- 2014-02-05 EP EP14748796.1A patent/EP2953646B1/en active Active
- 2014-02-05 CA CA2899155A patent/CA2899155A1/en not_active Abandoned
- 2014-02-05 ES ES14748796T patent/ES2873600T3/es active Active
- 2014-02-05 AU AU2014215421A patent/AU2014215421A1/en not_active Abandoned
- 2014-02-05 KR KR1020157024176A patent/KR20150132131A/ko not_active Withdrawn
- 2014-02-05 SG SG10201706968UA patent/SG10201706968UA/en unknown
- 2014-02-05 RU RU2015137815A patent/RU2015137815A/ru not_active Application Discontinuation
- 2014-02-05 SG SG11201506116XA patent/SG11201506116XA/en unknown
- 2014-02-05 MX MX2015010083A patent/MX2015010083A/es unknown
- 2014-02-05 JP JP2015556243A patent/JP6507102B2/ja active Active
-
2015
- 2015-07-26 IL IL240148A patent/IL240148A0/en unknown
- 2015-09-04 ZA ZA2015/06530A patent/ZA201506530B/en unknown
-
2018
- 2018-02-07 AU AU2018200903A patent/AU2018200903A1/en not_active Abandoned
-
2021
- 2021-04-06 US US17/223,647 patent/US20210230595A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513090A5 (enExample) | ||
| RU2015137815A (ru) | Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства | |
| Lim et al. | Polymeric nanoparticles in development for treatment of pulmonary infectious diseases | |
| KR101811917B1 (ko) | 점액 침투 강화를 나타내는 나노 입자 제형 | |
| Kumar et al. | Nanotechnology as emerging tool for enhancing solubility of poorly water-soluble drugs | |
| Zhao et al. | Dual-functional lipid polymeric hybrid pH-responsive nanoparticles decorated with cell penetrating peptide and folate for therapy against rheumatoid arthritis | |
| CN106793970B (zh) | 用于诊断及治疗的纳米载剂及其加工 | |
| KR101243689B1 (ko) | 미립자 및 의약품 조성물 | |
| US11850309B2 (en) | Cationic materials and formulations for drug delivery | |
| CN103040724B (zh) | 含聚合物与磷脂的纳米载药系统及其制备方法 | |
| He et al. | Recent development of poly (ethylene glycol)-cholesterol conjugates as drug delivery systems | |
| US20220175953A1 (en) | Biomimetic anisotropic polymeric particles with naturally derived cell membranes for enhanced drug delivery | |
| Cheng et al. | Cell-mediated nanoparticle delivery systems: towards precision nanomedicine | |
| Gupta et al. | Nanogel: A versatile drug delivery system for the treatment of various diseases and their future perspective | |
| Wang et al. | Advanced hitchhiking nanomaterials for biomedical applications | |
| KR100792557B1 (ko) | 나노 캡슐화를 이용하여 제조된 지질 핵 및 고분자 쉘구조를 갖는 단백질 약물 전달용 나노 미립구 | |
| CN104622817A (zh) | 一种蛋白-聚合物复合纳米载体及其制备方法 | |
| Naghib et al. | Stimuli-sensitive chitosan-based nanosystems-immobilized nucleic acids for gene therapy in breast cancer and hepatocellular carcinoma | |
| Chinnagounder Periyasamy et al. | Nanomaterials for the local and targeted delivery of osteoarthritis drugs | |
| Shi et al. | Advances in nanotherapy for targeting senescent cells | |
| CN111107842A (zh) | 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒 | |
| CN107519496B (zh) | 一类l-肉毒碱两亲性衍生物及其修饰的纳米粒及其用途 | |
| Ulku et al. | The importance of nanotechnology and drug carrier systems in pharmacology | |
| Barbosa et al. | Nanotechnology applied in drug delivery | |
| Saw et al. | Current Development of RNA Delivery Systems |